

IPCA Laboratories

BSE SENSEX 81,381 S&P CNX 24,964



Stock Info

| | IPCA IN |
|-----------------------|------------|
| Bloomberg | IPCA IN |
| Equity Shares (m) | 254 |
| M.Cap.(INRb)/(USDb) | 419.8 / 5 |
| 52-Week Range (INR) | 1659 / 933 |
| 1, 6, 12 Rel. Per (%) | 15/15/50 |
| 12M Avg Val (INR M) | 625 |
| Free float (%) | 53.7 |

Financials Snapshot (INR b)

| Y/E MARCH | FY25E | FY26E | FY27E |
|----------------------|-------|-------|-------|
| Sales | 88.9 | 101.6 | 119.6 |
| EBITDA | 17.2 | 20.2 | 24.9 |
| Adj. PAT | 8.5 | 10.9 | 14.2 |
| EBIT Margin (%) | 14.9 | 16.0 | 17.4 |
| Cons. Adj. EPS (INR) | 33.4 | 42.8 | 55.9 |
| EPS Gr. (%) | 60.8 | 28.1 | 30.5 |
| BV/Sh. (INR) | 278.0 | 314.4 | 362.0 |

Ratios

| | | | |
|------------|------|------|------|
| Net D:E | 0.3 | 0.2 | 0.1 |
| RoE (%) | 12.7 | 14.5 | 16.5 |
| RoCE (%) | 11.2 | 12.1 | 14.0 |
| Payout (%) | 22.0 | 17.9 | 19.2 |

Valuations


| | | | |
|----------------|------|------|------|
| P/E (x) | 49.6 | 38.7 | 29.7 |
| EV/EBITDA (x) | 24.6 | 20.9 | 17.0 |
| Div. Yield (%) | 0.5 | 0.5 | 0.7 |
| FCF Yield (%) | 1.1 | 2.2 | 2.4 |
| EV/Sales (x) | 4.8 | 4.2 | 3.5 |

Shareholding pattern (%)

| As On | Jun-24 | Mar-24 | Jun-23 |
|----------|--------|--------|--------|
| Promoter | 46.3 | 46.3 | 46.3 |
| DII | 33.8 | 34.4 | 35.2 |
| FII | 10.9 | 10.5 | 10.1 |
| Others | 9.1 | 8.8 | 8.5 |

FII Includes depository receipts

Stock performance (one-year)



CMP: INR1,659 TP: INR1,950 (+18%) Upgrade to Buy

At an inflexion point

- After three years of earnings deterioration, IPCA is well-poised to deliver strong earnings growth over FY24-27.
- With broad-based growth in volume and pricing, IPCA has been able to outperform the industry significantly in the domestic formulation (DF) market, with 15% YoY growth in MAT Aug'24 and a 15% CAGR in MAT Aug'21-24.
- IPCA is making efforts to augment its export prospects through new launches and market share gains in generics exports. It is also working to drive synergies from the Unichem acquisition.
- After a muted performance in the US generics business over the last 10 years due to compliance issues, IPCA is geared up to revive its US business through improving USFDA compliance, new launches over the next 6-8 months, and synergies from the Unichem acquisition.
- Considering a 29% earnings CAGR and an anticipated improvement in the return ratio to ~17% over FY24-26, we value IPCA at 38x 12M forward earnings to arrive at a TP of INR1950. We upgrade IPCA to BUY as we factor in better operational efficiency, a revival in US business, synergies from the Unichem acquisition, and well-established DF business.

DF: Geared up to sustain industry-beating growth

- Given the highest share of acute therapies in the DF market (68% of DF sales MAT Aug'24) and chronic therapies (32% of DF sales MAT Aug'24), IPCA has outperformed IPM consistently over MAT Aug'21-24, led by strong brand equity, efficient management of seasonality, increase in MR productivity and market share gain.
- IPCA's Cardiac/Anti-infective/Derma outperformed IPM by 6%/10.6%/13.1% in MAT Aug'24, led by superior execution.
- Although the pharma industry has been witnessing a decline in Pain therapy, IPCA has outperformed IPM by ~680bp over MAT Aug'21-24, led by strong execution and growth in its key brands, including Zerodol and combination.
- IPCA is focusing on improving MR productivity, new launches and market share gain in existing and new launches.
- We expect a 14% sales CAGR in the DF segment over FY25-27.

Exports: Healthy momentum in generics formulation business

- The company's export formulation business grew slowly at a CAGR of 3.6% over FY21-FY24, dragged down by a decline in its institutional business (-11.5%) and slower growth in its generics business (6.7% CAGR).
- We expect IPCA to deliver a 27% CAGR in exports over FY24-27 on the back of a healthy approval pace, a sound compliance record, and new product launches.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst: Akash Dobhada (Akash.Dobhada@MotilalOswal.com) | Viraj Shah (Viraj.Shah@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Valuation and view


- We believe that the positive factors for IPCA include strong domestic brand franchise, improved USFDA compliance, US business revival, synergic benefits of the Unichem acquisition, and improving operational efficiency.
- We value IPCA at 38x 12M forward earnings to arrive at a TP of INR1,950. We upgrade to BUY.

Exhibit 1: Valuation snapshot

| Company | Reco | MCap (USD B) | EPS (INR) | | | EPS Gr. YoY (%) | | PE (x) | | EV/EBITDA (x) | | ROE (%) | | |
|-------------------|-----------------------|-----------------|-------------|-------------|-------------|-----------------|-------------|-------------|-------------|---------------|-------------|------------|-------------|-------------|
| | | | FY24 | FY25E | FY26E | FY25E | FY26E | FY25E | FY26E | FY25E | FY26E | FY24 | FY25E | FY26E |
| Ajanta Pharma | Buy | 5.0 | 62.3 | 75.8 | 87.8 | 21.7 | 15.6 | 44.2 | 38.2 | 31.1 | 27.1 | 22.7 | 24.5 | 23.7 |
| Alembic Pharma | Neutral | 2.7 | 31.5 | 37.4 | 41.2 | 18.8 | 10.3 | 31.4 | 28.4 | 19.3 | 17.2 | 13.5 | 14.2 | 13.9 |
| Alkem Lab | Neutral | 8.7 | 159.7 | 187.8 | 204.3 | 17.6 | 8.8 | 32.9 | 30.2 | 27.9 | 25.5 | 19.7 | 20.1 | 18.8 |
| Aurobindo Pharma | Neutral | 10.2 | 56.0 | 66.3 | 73.8 | 18.3 | 11.3 | 22.5 | 20.3 | 11.6 | 10.7 | 11.6 | 12.3 | 12.2 |
| Biocon | Neutral | 4.9 | 1.8 | 4.4 | 9.2 | 144.4 | 109.8 | 78.5 | 37.4 | 16.1 | 12.6 | 1.1 | 2.6 | 5.3 |
| Cipla | Buy | 15.5 | 52.5 | 58.7 | 65.6 | 11.9 | 11.7 | 27.2 | 24.3 | 18.0 | 15.7 | 15.9 | 15.4 | 14.9 |
| Divi's Lab. | Neutral | 18.8 | 60.0 | 77.7 | 95.1 | 29.6 | 22.4 | 79.0 | 64.5 | 53.8 | 44.9 | 12.1 | 14.4 | 15.9 |
| Dr Reddy's Labs | Neutral | 13.0 | 317.1 | 353.8 | 389.0 | 11.6 | 9.9 | 18.7 | 17.0 | 11.0 | 9.2 | 20.7 | 19.1 | 17.7 |
| Eris Lifescience | Neutral | 2.3 | 29.2 | 30.4 | 42.0 | 4.0 | 38.0 | 45.5 | 33.0 | 17.7 | 15.4 | 16.8 | 15.2 | 18.2 |
| Gland Pharma | Buy | 3.3 | 47.6 | 53.4 | 67.0 | 12.1 | 25.6 | 31.8 | 25.3 | 17.8 | 14.4 | 9.4 | 9.6 | 10.9 |
| Glenmark Pharma | Buy | 5.9 | 2.5 | 47.5 | 59.2 | 1811.9 | 24.6 | 37.8 | 30.3 | 19.5 | 16.1 | 0.8 | 15.8 | 16.8 |
| Glaxosmit Pharma | Neutral | 5.6 | 43.3 | 48.1 | 53.4 | 11.1 | 11.1 | 57.9 | 52.1 | 42.9 | 38.1 | 41.3 | 38.3 | 35.3 |
| Granules India | Buy | 1.7 | 17.4 | 22.2 | 29.4 | 27.7 | 32.8 | 27.2 | 20.5 | 14.5 | 11.8 | 13.9 | 15.4 | 17.5 |
| Ipca Labs. | Upgrade to Buy | 4.8 | 20.8 | 33.5 | 43.0 | 61.3 | 28.2 | 49.4 | 38.5 | 24.9 | 20.8 | 8.7 | 12.7 | 14.5 |
| Laurus Labs | Buy | 2.9 | 3.0 | 6.7 | 11.9 | 121.9 | 78.3 | 70.8 | 39.7 | 24.7 | 18.8 | 4.0 | 8.4 | 13.7 |
| Lupin | Neutral | 11.6 | 41.5 | 59.2 | 69.8 | 42.5 | 17.8 | 37.6 | 31.9 | 21.3 | 17.9 | 14.1 | 17.3 | 17.4 |
| Mankind Pharma | Buy | 12.8 | 47.8 | 54.5 | 62.4 | 14.1 | 14.6 | 51.3 | 44.7 | 34.6 | 29.5 | 22.8 | 21.4 | 20.9 |
| Piramal Pharma | Buy | 3.4 | 0.4 | 2.6 | 5.3 | 509.3 | 107.2 | 85.8 | 41.4 | 21.8 | 16.1 | 0.8 | 4.2 | 8.2 |
| Sun Pharma.Inds. | Buy | 53.9 | 41.4 | 49.2 | 57.9 | 18.6 | 17.8 | 38.7 | 32.8 | 30.5 | 26.4 | 16.7 | 17.2 | 17.4 |
| Torrent Pharma. | Neutral | 13.9 | 47.1 | 63.4 | 82.0 | 34.6 | 29.3 | 55.2 | 42.7 | 29.2 | 24.5 | 24.4 | 28.5 | 30.5 |
| Zydus LifeScience | Neutral | 12.6 | 37.6 | 43.9 | 47.3 | 16.5 | 7.9 | 24.3 | 22.5 | 15.9 | 14.3 | 20.3 | 19.6 | 17.4 |

Source: MOFSL, Company

Pain is IPCA's biggest therapy, contributing 39% to DF sales




Outperforming DF market with strong brands and strategic execution

- In 5MFY25/MAT Aug'24, IPCA has outperformed IPM by 6.3%/6.7%, led by strong brand equity, improved productivity and increase in volumes.
- In MAT Aug'24, acute therapies (68% of DF business)/Chronic therapies (32% of DF business) outperformed IPM by 6.3%/8.3%.
- Pain therapy (~39% of total DF revenue) grew 13.6% YoY in MAT Aug'24, led by 14 % YoY growth in Zerodol and combination.
- Cardiac/Anti-infective/Derma outperformed IPM by 6%/10.6%/13.1% in MAT Aug'24, led by superior execution.
- Supported by new product launches and market share gains, we expect the DF segment to grow at 14% over FY25-27.

Strong brand equity paves way for IPM outperformance


- During MAT Aug'24, IPCA grew 14.8% YoY, outperforming IPM by 670bp, on the back of 7.7%/6.1%/1% growth in price/volume/New launches.
- In FY23 and FY24, although IPCA outperformed IPM, its YoY growth declined due to the high base of Covid and moderate growth in key therapies like Anti-infectives. Strong brand equity led to consistent outperformance against IPM over FY19-24.
- Despite having 17% of its portfolio under the National List of Essential Medicines (NLEM), IPCA has consistently outperformed IPM since FY19. This can be attributed to strong brand recall, effective management of seasonality, a rise in volume, decluttering the MRs for enhanced brand focus, and improved productivity.

Exhibit 2: IPCA has 17% of its portfolio under NLEM



Source: MOFSL, company

Exhibit 3: IPCA consistently outperforming IPM



Source: MOFSL, company, IQVIA


Strong brand equity led to consistent outperformance against IPM over FY19-24

- IPCA has posted a CAGR of 16% over FY21-24, outperforming IPM by ~480bp. IPCA outperformed IPM in Derma/Pain/Anti-Infectives by 21.7%/5.2%/1.7% over FY21-24.
- In FY21, although IPCA outperformed IPM, DF growth declined YoY to 9.5% due to the adverse impact of the Covid lockdown, leading to temporary disturbances in the supply chain. However, in FY22, the company registered a phenomenon growth of 19.7% YoY, due to rising demand on account of Covid-19, higher growth in the respiratory division, and a low base of FY21.

Broad-based growth across therapies over past 12 months


- During MAT Aug'24, IPCA's growth was attributed to strong outperformance in Acute (+630bp vs. IPM) and Chronic (+830bp vs. IPM).
- Over MAT Aug'20-24, IPCA's acute therapies (68% of DF sales) saw a 16.1% CAGR and chronic therapies (32% of DF sales) clocked a 15.4% CAGR.

Exhibit 4: Acute therapies and...



Source: MOFSL, IQVIA

Exhibit 5: ... chronic therapies continues to outperform IPM



Source: MOFSL, IQVIA

Exhibit 6: Except Antineoplast, all other therapies have outperformed IPM

| Therapy | MAT AUG'24 | 4 Year CAGR (%) | IPCA YoY (%) | IPM YoY (%) |
|------------------------------|------------|-----------------|--------------|-------------|
| Pain / Analgesics | 1,777 | 18 | 14 | 8 |
| Cardiac | 583 | 12 | 17 | 11 |
| Anti-Infectives | 344 | 8 | 11 | 6 |
| Derma | 255 | 24 | 20 | 7.2 |
| Antineoplast/Immunomodulator | 243 | 19 | 16 | 20.3 |
| Gastro Intestinal | 225 | 8 | 10 | 9.6 |
| Respiratory | 204 | 20 | 4 | 2.7 |
| Urology | 202 | 35 | 33 | 13.3 |
| Anti Malarials | 193 | 1 | 15 | 14.2 |
| Neuro / Cns | 184 | 19 | 13 | 8.6 |
| Anti Diabetic | 160 | 10 | 22 | 7.1 |


Source: MOFSL, IQVIA

IPM outperformance across both acute and chronic therapies

IPCA outperforming IPM despite industry slowdown in Pain segment

- Pain therapy in IPM has been on a downward trend, from 16% YoY in MAT Aug'21 to 8% YoY in MAT Aug'24. Despite the slowdown, IPCA has consistently outperformed IPM by ~680bp over the same period owing to strong brand equity. Pain therapy accounted for 39% of IPCA's total DF sales in MAT Aug'24.
- In MAT Aug'21-22, the pain segment saw significant growth, driven by a surge in demand for hydroxychloroquine during the Covid-19 pandemic. However, excluding growth of hydroxychloroquine, the Pain segment witnessed growth in mid-single digits.


Exhibit 7: IPCA consistently outperforms IPM in Pain



MAT Aug'21 MAT Aug'22 MAT Aug'23 MAT Aug'24

Source: MOFSL, IQVIA

Exhibit 8: In MAT Aug'24, IPCA outperformed IPM with a wide margin in Cardiac



MAT Aug'21 MAT Aug'22 MAT Aug'23 MAT Aug'24

Source: MOFSL, IQVIA


Strong revival in Cardiac therapy over past 12 months

- In MAT Aug'24, IPCA's cardiac therapy (12.8% of DF sales) outperformed IPM growth by 600bp, led by strong brand growth and MR productivity improvement.
- In MAT Aug'23, the cardiac segment showed healthy growth of 9.9%, though it still underperformed as one division remained in the breakeven phase.
- In MAT Aug'22, growth in the cardiac segment was subdued due to the launch of two new divisions aimed at increasing consultant-level penetration and restructuring the existing distribution network, leading to a decline in growth.
- In MAT Aug'21, IPCA's cardiac therapy saw its highest growth, driven by the introduction of sartan into the product portfolio.

Superior execution in Anti-infective therapy

- In MAT Aug'24, IPCA outperformed IPM in Anti-infective therapy (7.6% of Ipcas DF sales), led by the seasonality effect and a strong brand recall of the company. In MAT Aug'23, growth in Anti-infective therapy was low despite good growth in IPM. This was due to the high base effect of last year and seasonality.


Exhibit 9: In MAT Aug'24, IPCA outperformed IPM in Anti-infective therapy



MAT Aug'21 MAT Aug'22 MAT Aug'23 MAT Aug'24

Source: MOFSL, IQVIA

Exhibit 10: Consistent strong double-digit growth in Derma therapy since MAT Aug'21



MAT Aug'21 MAT Aug'22 MAT Aug'23 MAT Aug'24

Source: MOFSL, IQVIA

Robust high-teens YoY growth in derma therapy for IPCA

- As of Aug’24, IPCA’s Derma therapy outpaced IPM, with 13.1% YoY growth, led by the, strong brand recall, increase in productivity, new launches and strong execution.
- Over MAT Aug’21-24, the therapy consistently achieved high double-digit growth, reflecting strong performance in this segment.
- The Derma therapy has outperformed IPM by ~28.5% over MAT Aug’21-22 led by low base effect of covid-19.

Top brands growing faster than IPM

- ZERODOL-SP is used in pain management related to inflammation relief, swelling and aids faster recovery of inflamed or injured tissues. The drug has registered a 24.4% CAGR over the past four years, surpassing the growth of therapy as well as molecule, indicating strong brand equity and enhanced productivity of the specialized division.
- Further, ZERODOL-SP is superior to ZERODOL-P, owing to the introduction of Serrapeptase molecule, resulting in a reduction of inflammation and edema (swelling) and promoting faster tissue repair compared to ZERODOL-P.

Exhibit 11: Except HCQ and CTD, all other brands are growing in high double digits

| Top 10 brands | Therapy | Molecule | MAT Aug'24 INRm | YoY Growth % | 4 Year Brand CAGR | 4 years Therapy CAGR % | 4 Years molecule CAGR % |
|---------------|--------------|--|-----------------|--------------|-------------------|------------------------|-------------------------|
| Zerodol-sp | Pain | Aceclofenac + Paracetamol + Serrapeptase | 5766 | 18.2 | 24.4 | 12.2 | 19.7 |
| Zerodol-p | Pain | Aceclofenac + Paracetamol | 2905 | 7.6 | 14.5 | 12.2 | 11.1 |
| Hcqs | Pain | Hydroxychloroquine Sulfate | 1926 | 7.4 | 5.3 | 12.2 | 4 |
| Folitrax | Antineoplast | Methotrexate And Comb. | 1358 | 14.3 | 15.3 | 21.5 | 15.1 |
| Zerodol-th | Pain | Aceclofenac + Thiocolchicoside | 1248 | 9.3 | 15.8 | 12.2 | 11.4 |
| Ctd-t | Cardiac | Chlortalidone + Telmisartan | 1113 | 31.0 | 18.6 | 10.8 | 12.6 |
| Solvin cold | Respiratory | Chlorphenamine Maleate + Paracetamol + Phenylephrine Hydrochloride | 928 | 4.0 | 16.8 | 10.4 | 6.8 |
| Ctd | Cardiac | Chlortalidone | 784 | 9.7 | 7.6 | 10.8 | 7.3 |
| Tfct-nib | Pain/Derma | Tofacitinib Citrate | 757 | 25.2 | 66* | 12.2 | 127.4 |
| Pacimol | Pain | Paracetamol | 712 | 16.4 | 14.5 | 12.2 | 13.9 |

*Note: TFCT-NIB brand growth is take for 3 years, Source: MOFSL, IQVIA


Low base, higher productivity and new introduction led to 21% outperformance of Derma therapy vs, IPM

- CTD brand has seen moderate growth of 7.6% over the last four years and has underperformed the cardiac therapy. CTD is used for reducing fluid and salt in the body to lower blood pressure.
- While CTD-T is a combination drug of Chlortalidone + Telmisartan, it provides a stronger and more comprehensive control of high blood pressure by targeting both fluid reduction and blood vessel relaxation.
- This has resulted in faster growth of CTD-T (18.6% CAGR over last 4 years) vs. CTD (7.6% CAGR over same period). Further CTD-T is growing faster than the molecule and therapy.

TFCT-NIB growth strong, albeit losing market share on price competition


- Osteoarthritis (OA) is the most common rheumatic disease and the 4th most common cause of disability worldwide.
- IPCA’s arthritis drug TFCT-NIB was launched in 2021 and has grown at a CAGR of 66% in the past three years to INR757m.

Exhibit 12: IPCA’s Tofacitinib drug at ~68% premium over peer average.....



Source: MOFSL, Company, Tata 1MG

Exhibit 13: leading to high price competition and loss of market share



Source: MOFSL, Company, IQVIA


- While TFCT-NIB has seen the fastest growth among other drugs of the company, it still lags behind Tofacitinib market growth of 78% over Aug’21-Aug’24.
- The key reason is that TFCT-NIB is priced at a ~68% premium to average peer pricing in the Tofacitinib market, leading to ~470bp market share loss over Aug’21 to Aug’24 to 21%.
- India’s elderly population (>60 years) is set to increase drastically from around 7.4% in 2001 to around 19% in 2050.

New in-licensing deals/superior execution aid IPCA to outperform IPM

IPCA is well positioned to outperform IPM with 14% CAGR

- As of Aug’24, IPCA received marketing rights for Novalead’s patented drug, Diulicus, for the treatment of diabetic foot ulcer. Owing to a high diabetes rate among people, this deal would help IPCA grow over the medium to long term.
- Accordingly, we expect DF sales to clock a CAGR of 14% over FY25-27 to INR50b.

Exhibit 14: DF business to register a CAGR of 14% over FY25-27



Source: MOFSL, Company


Synergies of Unichem, approvals to boost exports

- After the acquisition, Unichem’s revenue grew 16% YoY from Dec’23 to Jun’24.
- IPCA’s North America (NA) business grew by a meager 7% over FY18-24, due to regulatory issues at its three sites. After the clearance of the site and the synergic benefits of Unichem, we expect a faster revival in business.
- The regulatory compliance at IPCA/Unichem sites and the ongoing product development exercise should start showing commercial benefits after 6-7 months.
- We expect export formulation business to register a CAGR of 28% over FY24-27.

Ipca scaling up Unichem business through cost efficiency and new launches


- Unichem business, after the consolidation in Sep’23, grew 16% YoY over Dec’23-Jun’24. Driven by efficient cost optimization, Unichem’s EBITDA margins expanded by 310bp YoY to 9.7% in 1QFY25.
- The US remains a key market for the company, with ~58% contribution to total Unichem revenue and 40% YoY growth in FY24.
- As of Mar’24, Unichem had 75+ ANDAs and 77 DMF across markets and therapeutic categories.

Exhibit 15: Unichem is improving on operating parameters



Source: MOFSL, Company

Exhibit 16: Total ANDA filings stood at 75+ as of FY24



Source: MOFSL, Company

- Bayshore Pharmaceuticals LLC, a subsidiary of IPCA Labs, sold all rights in the product approvals and all goodwill associated with 9 ANDAs to Unichem for USD2.7m. Unichem Pharmaceuticals (USA) Inc. will also purchase Bayshore’s US generics formulation marketing and distribution business for USD10m.
- Aligning Bayshore’s generic portfolio would help Unichem generate synergies, improve efficiency and expand product offerings.

Work in progress to revive US business

- Over the last six years (FY18-24), IPCA’s NA sales have grown by a meager 7%, due to the import alert on its three facilities in the US.
- Over the past 10 years, IPCA had no business in the US market and had no development pipeline for the US market.
- However, after the clearance of the three sites, IPCA is working on filing new products in the US market, which would yield benefits over the medium term.
- Further, with the integration of Unichem business, IPCA would restructure its US business faster. Furthermore, the company is also foraying into biosimilar business, which would benefit over the longer term.

USFDA compliance at sites provides comfort for better US prospects

- On the compliance front, IPCA had a rough history with the USFDA. Over the past eight years, Ratlam and Silvassa plants were under the import alert.
- However, after the recent inspection completed in Jun'23/Apr'23 for Dhar/Ratlam/Silvassa, IPCA's facilities are in compliance with the regulatory norms of the USFDA.
- IPCA is working on its product pipeline and would file ANDA after 6-8 months.

Exhibit 17: All facilities are compliant to USFDA regulations

| Company | City | Inspection End Date | Classification |
|---------|-----------------|---------------------|----------------|
| IPCA | Dhar | Jun-23 | VAI |
| | Ratlam | Jun-23 | VAI |
| | Silvassa | Apr-23 | VAI |
| | Silvassa | Aug-19 | OAI |
| Unichem | Pilerne Bardez | Jul-24 | VAI |
| | Ghaziabad | Feb-24 | NAI |
| | East Brunswick | Sep-23 | NAI |
| | District Raigad | Feb-20 | NAI |
| | Pilerne Bardez | Jan-20 | VAI |


Note: NAI- No Action Indicated, VAI- Voluntary Action Indicated, OAI- Official Action Indicated,
Source: MOFSL, Company, USFDA

- On the other hand, Unichem has a sound compliance record. Since 2009, it has witnessed 28 USFDA inspections, with an outcome of either NAI/VAI.
- With the acquisition of Unichem business, IPCA is trying to revive the US business through its USFDA-compliant facilities and reach.

Export business to grow as generics business expands


- Formulation business (62% of total revenue) is expected to clock a CAGR of 18%, driven by 27% growth in exports over FY24-FY27E.
- Export growth (36% of formulation revenue) is expected to be driven by 39% growth in generics over FY24-FY27E, aided by a favorable pricing environment, market share gains, Unichem consolidation, and new product launches.
- Branded formulation exports have been under pressure owing to high exposure to countries like Russia, Kazakhstan and Belarus, which have been impacted by geopolitical conflicts. However, with geographic diversification and easing pressure, we expect branded formulation exports to post a CAGR of 33% over FY25-FY27.

Exhibit 18: Export formulation business to register a CAGR of 28% over FY24-27




Source: MOFSL, Company

Exhibit 19: IPCA PE Chart




Source: MOFSL, Company

Exhibit 20: IPCA EV/EBITDA Chart




Source: MOFSL, Company

Exhibit 21: Healthcare PE Chart



Source: MOFSL, Company


Exhibit 22: Healthcare EV/EBITDA Chart



Source: MOFSL, Company


Story in charts

Exhibit 23: Expect 23% revenue CAGR over FY25-27




Source: Company, MOFSL

Exhibit 24: Expect India sales CAGR of 14% over FY25-27




Source: Company, MOFSL

Exhibit 25: Expect 33% export sales CAGR over FY25-27




Source: Company, MOFSL

Exhibit 26: EBITDA margin to expand over FY25-27




Source: Company, MOFSL

Exhibit 27: ROCE/ROE to improve over FY25-27



Source: Company, MOFSL

Exhibit 28: Expect 29% earnings CAGR over FY25-27



Source: Company, MOFSL

Financials and valuations

| Income Statement | | | | | | | (INRm) | | |
|------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|-----------------|-----------------|
| Y/E March | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25E | FY26E | FY27E |
| Net Revenues | 37,732 | 46,487 | 54,200 | 58,298 | 62,569 | 77,074 | 88,904 | 1,01,567 | 1,19,621 |
| Change (%) | 14.9 | 23.2 | 16.6 | 7.6 | 7.3 | 23.2 | 15.3 | 14.2 | 17.8 |
| EBITDA | 7,170 | 9,580 | 15,444 | 13,509 | 9,812 | 13,076 | 17,158 | 20,212 | 24,881 |
| Margin (%) | 19.0 | 20.6 | 28.5 | 23.2 | 15.7 | 17.0 | 19.3 | 19.9 | 20.8 |
| Depreciation | 1,824 | 2,105 | 2,092 | 2,324 | 2,616 | 3,572 | 3,902 | 3,926 | 4,082 |
| EBIT | 5,346 | 7,475 | 13,352 | 11,184 | 7,197 | 9,503 | 13,256 | 16,286 | 20,799 |
| Int. and Finance Charges | 189 | 165 | 90 | 77 | 455 | 1,383 | 969 | 950 | 896 |
| Other Income - Rec. | 483 | 578 | 457 | 666 | 1,151 | 1,075 | 900 | 950 | 980 |
| PBT before EO Expense | 5,640 | 7,888 | 13,719 | 11,773 | 7,892 | 9,195 | 13,187 | 16,286 | 20,883 |
| EO Expense/(Income) | 157 | 445 | -171 | 416 | 314 | 769 | 0 | 0 | 0 |
| PBT after EO Expense | 5,483 | 7,442 | 13,890 | 11,357 | 7,579 | 8,426 | 13,187 | 16,286 | 20,883 |
| Current Tax | 1,218 | 1,406 | 2,487 | 2,070 | 2,302 | 3,102 | 3,890 | 4,641 | 5,931 |
| Deferred Tax | -176 | -53 | -85 | 178 | 230 | 33 | 264 | 326 | 418 |
| Tax | 1,042 | 1,353 | 2,401 | 2,248 | 2,532 | 3,135 | 4,154 | 4,967 | 6,348 |
| Tax Rate (%) | 18.5 | 17.2 | 17.5 | 19.1 | 32.1 | 34.1 | 31.5 | 30.5 | 30.4 |
| Reported PAT | 4,441 | 6,090 | 11,488 | 9,110 | 5,047 | 5,291 | 9,032 | 11,317 | 14,533 |
| Less: Minority Interest | 18 | 78 | 91 | 269 | -206 | 984 | 550 | 450 | 350 |
| Net Profit | 4,423 | 6,012 | 11,398 | 8,841 | 5,253 | 4,307 | 8,482 | 10,867 | 14,183 |
| Adj PAT | 4,580 | 6,485 | 11,255 | 9,218 | 5,275 | 5,274 | 8,482 | 10,867 | 14,183 |
| Adj PAT growth (%) | 91.3 | 41.6 | 73.6 | -18.1 | -42.8 | 0.0 | 60.8 | 28.1 | 30.5 |

| Balance Sheet | | | | | | | (INRm) | | |
|------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|-----------------|-----------------|
| Y/E March | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25E | FY26E | FY27E |
| Equity Share Capital | 252 | 252 | 254 | 254 | 254 | 254 | 254 | 254 | 254 |
| Total Reserves | 30,971 | 35,903 | 46,763 | 54,666 | 58,167 | 63,068 | 70,279 | 79,517 | 91,574 |
| Net Worth | 31,224 | 36,275 | 47,017 | 54,920 | 58,420 | 63,322 | 70,533 | 79,771 | 91,828 |
| Deferred liabilities | 1457 | 1398 | 1316 | 1506 | 1856 | 3062 | 3326 | 3652 | 4070 |
| Total Loans | 3,505 | 4,328 | 1,988 | 8,027 | 14,746 | 14,274 | 24,474 | 23,047 | 21,763 |
| Capital Employed | 36,342 | 42,137 | 50,466 | 65,222 | 75,755 | 94,607 | 98,333 | 1,06,470 | 1,17,660 |
| Gross Block | 26,657 | 30,268 | 31,872 | 37,647 | 43,601 | 65,195 | 66,695 | 68,195 | 69,695 |
| Less: Accum. Deprn. | 6,951 | 9,056 | 11,148 | 13,472 | 16,088 | 19,660 | 23,562 | 27,488 | 31,570 |
| Net Fixed Assets | 19,706 | 21,212 | 20,724 | 24,175 | 27,514 | 45,535 | 43,133 | 40,707 | 38,125 |
| Capital WIP | 361 | 708 | 2,348 | 3,064 | 1,404 | 3,429 | 3,429 | 3,429 | 3,429 |
| Investments | 1,204 | 2,719 | 4,711 | 9,892 | 6,260 | 8,620 | 8,620 | 8,620 | 8,620 |
| Curr. Assets | 24,217 | 27,939 | 32,881 | 39,237 | 51,051 | 53,386 | 58,496 | 71,245 | 88,133 |
| Inventory | 10,725 | 13,231 | 15,948 | 18,580 | 17,434 | 24,713 | 27,524 | 30,888 | 36,050 |
| Account Receivables | 6,815 | 8,952 | 8,118 | 9,108 | 9,890 | 16,865 | 19,729 | 22,818 | 26,874 |
| Cash and Bank Balance | 2,823 | 1,809 | 3,651 | 6,407 | 18,532 | 2,968 | 1,047 | 5,891 | 11,490 |
| Loans & Advances | 3,854 | 3,947 | 5,164 | 5,143 | 5,194 | 8,840 | 10,196 | 11,649 | 13,719 |
| Curr. Liability & Prov. | 9,147 | 10,441 | 10,198 | 11,147 | 10,473 | 16,364 | 15,345 | 17,531 | 20,647 |
| Account Payables | 8,190 | 9,182 | 8,781 | 9,704 | 8,923 | 13,050 | 13,640 | 15,583 | 18,353 |
| Provisions | 957 | 1,259 | 1,417 | 1,443 | 1,550 | 3,314 | 1,705 | 1,948 | 2,294 |
| Net Current Assets | 15,070 | 17,498 | 22,682 | 28,091 | 40,577 | 37,022 | 43,151 | 53,714 | 67,486 |
| Appl. of Funds | 36,342 | 42,137 | 50,466 | 65,222 | 75,755 | 94,607 | 98,333 | 1,06,470 | 1,17,660 |

E: MOFSL Estimates

Financials and valuations

| Ratios | | | | | | | | | |
|---------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Y/E March | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25E | FY26E | FY27E |
| EPS (INR) | 18.1 | 25.6 | 44.4 | 36.3 | 20.8 | 20.8 | 33.4 | 42.8 | 55.9 |
| Cash EPS | 24.8 | 32.2 | 53.2 | 44.0 | 31.0 | 31.1 | 48.8 | 58.3 | 72.0 |
| BV/Share | 123.7 | 143.2 | 185.3 | 216.5 | 230.3 | 249.6 | 278.0 | 314.4 | 362.0 |
| DPS | 0.5 | 3.6 | 6.8 | 6.6 | 7.7 | 7.8 | 7.9 | 8.1 | 11.1 |
| Payout (%) | 2.8 | 14.8 | 14.9 | 18.3 | 38.3 | 36.9 | 22.0 | 17.9 | 19.2 |
| Valuation (x) | | | | | | | | | |
| P/E | 91.9 | 64.9 | 37.4 | 45.7 | 79.8 | 79.8 | 49.6 | 38.7 | 29.7 |
| P/BV | 13.4 | 11.6 | 9.0 | 7.7 | 7.2 | 6.6 | 6.0 | 5.3 | 4.6 |
| EV/Sales | 11.2 | 9.1 | 7.8 | 7.2 | 6.8 | 5.5 | 4.8 | 4.2 | 3.5 |
| EV/EBITDA | 58.9 | 44.1 | 27.4 | 31.3 | 43.1 | 32.3 | 24.6 | 20.9 | 17.0 |
| Dividend Yield (%) | 0.0 | 0.2 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.7 |
| Return Ratios (%) | | | | | | | | | |
| RoE | 15.8 | 19.2 | 27.1 | 18.1 | 9.3 | 8.7 | 12.7 | 14.5 | 16.5 |
| RoCE | 14.3 | 17.7 | 25.4 | 17.1 | 8.3 | 9.2 | 11.2 | 12.1 | 14.0 |
| RoIC | 14.0 | 18.0 | 28.7 | 21.1 | 10.2 | 9.7 | 11.0 | 13.0 | 15.9 |
| Working Capital Ratios | | | | | | | | | |
| Fixed Asset Turnover (x) | 1.9 | 2.3 | 2.6 | 2.6 | 2.4 | 2.1 | 2.0 | 2.4 | 3.0 |
| Debtor (Days) | 65 | 70 | 54 | 56 | 58 | 80 | 81 | 82 | 82 |
| Inventory (Days) | 104 | 104 | 107 | 116 | 102 | 117 | 113 | 111 | 110 |
| Working Capital Turnover (Days) | 118 | 123 | 128 | 136 | 129 | 161 | 173 | 172 | 171 |
| Leverage Ratio (x) | | | | | | | | | |
| Interest Cover Ratio | 28.3 | 45.3 | 147.7 | 145.4 | 15.8 | 6.9 | 13.7 | 17.1 | 23.2 |
| Debt/Equity | 0.0 | 0.1 | 0.0 | 0.0 | -0.1 | 0.2 | 0.3 | 0.2 | 0.1 |

Cash Flow Statement

(INR m)

| Y/E March | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25E | FY26E | FY27E |
|--|---------------|---------------|---------------|----------------|---------------|----------------|---------------|---------------|---------------|
| Oper. Profit/(Loss) before Tax | 7,170 | 9,580 | 15,444 | 13,509 | 9,812 | 13,076 | 17,158 | 20,212 | 24,881 |
| Interest/Dividends Recd. | 483 | 578 | 457 | 666 | 1,151 | 1,075 | 900 | 950 | 980 |
| Direct Taxes Paid | -1,165 | -1,412 | -2,484 | -2,058 | -2,181 | -1,928 | -3,890 | -4,641 | -5,931 |
| (Inc)/Dec in WC | -1,686 | -3,442 | -3,343 | -2,652 | -361 | -12,009 | -8,050 | -5,719 | -8,173 |
| CF from Operations | 4,803 | 5,304 | 10,075 | 9,464 | 8,421 | 213 | 6,118 | 10,801 | 11,757 |
| Others | 365 | 784 | | | | | | | |
| EO Expense / (Income) | 157 | 445 | -171 | 416 | 314 | 769 | 0 | 0 | 0 |
| CF from Oper. incl EO Exp. | 5,010 | 5,643 | 10,246 | 9,048 | 8,107 | -556 | 6,118 | 10,801 | 11,757 |
| (inc)/dec in FA | -1,632 | -3,958 | -3,244 | -6,491 | -4,294 | -23,618 | -1,500 | -1,500 | -1,500 |
| Free Cash Flow | 3,379 | 1,685 | 7,002 | 2,557 | 3,813 | -24,174 | 4,618 | 9,301 | 10,257 |
| (Pur)/Sale of Investments | -336 | -1,515 | -1,992 | -5,181 | 3,632 | -2,360 | 0 | 0 | 0 |
| Others | 317 | 376 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CF from Investments | -1,651 | -5,097 | -5,236 | -11,672 | -662 | -25,979 | -1,500 | -1,500 | -1,500 |
| Issue of shares | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| (Inc)/Dec in Debt | -1,070 | 804 | -2,331 | 6,663 | 6,683 | 12,743 | -3,748 | -1,427 | -1,284 |
| Interest Paid | -189 | -165 | -90 | -77 | -455 | -1,383 | -969 | -950 | -896 |
| Dividend Paid | -126 | -902 | -1,710 | -1,670 | -1,933 | -1,950 | -1,989 | -2,029 | -2,790 |
| CF from Fin. Activity | -1,832 | -1,305 | -3,169 | 5,222 | 4,681 | 10,705 | -5,816 | -3,338 | -3,803 |
| Inc/Dec of Cash | 1,528 | -758 | 1,841 | 2,598 | 12,126 | -15,830 | -1,198 | 5,963 | 6,455 |
| Add: Beginning Balance | 2,181 | 3,709 | 2,954 | 4,795 | 7,393 | 19,519 | 3,689 | 2,491 | 8,454 |
| Forex/ Business acquisition | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Closing Balance | 3,709 | 2,954 | 4,795 | 7,393 | 19,519 | 3,689 | 2,491 | 8,454 | 14,909 |
| Bank balances / Mutual fund (gain)/ loss | -886 | -1,145 | -1,145 | -986 | -986 | -721 | -741 | 2,564 | 3,419 |
| Closing Balance | 2,823 | 1,809 | 3,650 | 6,407 | 18,533 | 2,968 | 1,750 | 5,891 | 11,490 |

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

| Explanation of Investment Rating | |
|----------------------------------|--|
| Investment Rating | Expected return (over 12-month) |
| BUY | >=15% |
| SELL | < - 10% |
| NEUTRAL | < - 10 % to 15% |
| UNDER REVIEW | Rating may undergo a change |
| NOT RATED | We have forward looking estimates for the stock but we refrain from assigning recommendation |

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOFSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore. Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL .

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

| Contact Person | Contact No. | Email ID |
|--------------------|-----------------------------|------------------------------|
| Ms. Hemangi Date | 022 40548000 / 022 67490600 | query@motilaloswal.com |
| Ms. Kumud Upadhyay | 022 40548082 | servicehead@motilaloswal.com |
| Mr. Ajay Menon | 022 40548083 | am@motilaloswal.com |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CD SL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI:

ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.